Move to topTop

TOKYO, JAPAN and LEUVEN, BELGIUM - February 26, 2018 - Tokyo-based Terumo Corporation (TSE: 4543) has today announced that Terumo Pharmaceutical Solutions has been awarded the Asia-Pacific Bioprocessing Excellence Award 2018 on January 31st at the 5th Biologics Manufacturing Asia & 2nd Biologistics World Asia 2018 conference awards night held in Singapore.

Terumo Pharmaceutical Solutions was nominated in the category, 'Best Bioprocessing Supplier Award: Formulation & Fill-Finish' and competed with several other established companies in the industry.

Hideo Arase, Director and Senior Executive Officer, Terumo Corporation, Managing Director, Terumo Asia Holdings and Ashit Sikka, Director, Terumo Pharmaceutical Solutions, India accepted this award on the night on behalf of Terumo.

"Terumo is extremely honoured to receive this prestigious award in recognition of solution providers with platform technologies that have helped achieve astounding growth in the biomanufacturing space", said Hidehiko Oshima, President, Terumo Pharmaceutical Solutions.

"We are tremendously excited about the interest our PLAJEX™ platform has received in the market and we look forward to supporting our customer's future requirements", added Marco Chiadò Piat, Vice President, Terumo Pharmaceutical Solutions.

The Asia-Pacific Bioprocessing Excellence Award organized by IMAPAC, seeks to give recognition to exceptional bioprocessing experts, organizations and technologies that facilitate biomanufacturing excellence at enhanced speed, reduced cost and superior quality. Featuring top bioprocessing and biomanufacturing leaders in the industry, along with the latest advances in technologies and best practices in manufacturing, the Asia-Pacific Bioprocessing Excellence Awards applaud extraordinary leaders & trend-setters of today, and inspire innovators of tomorrow.

An esteemed panel of expert judges and the Biologics Manufacturing Asia committee shortlisted the nominees that have proven to be outstanding in their respective categories. They include key opinion leaders with more than 20 years of experience, Process Development Vice Presidents and Directors, Heads of Manufacturing and bioprocessing from all the key players in both Asia and on a global level.

About Terumo Pharmaceutical Solutions

Terumo Pharmaceutical Solutions has been crafting drug delivery devices for generations. Our unique skillset is based on the utmost care - for our industry, our customers and the patients whose quality of life depends on the highest level of healthcare.

Our business relationships are founded on precision, a strong work ethic and open dialogue. We pride ourselves on understanding your needs, anticipating new trends and maintaining constant dialogue with the pharmaceutical industry.

With almost 100 years of experience, we offer a full portfolio of scientific expertise and industry know-how. Our skills range from product design and development to logistics, regulatory affairs, clinical affairs and numerous business processes. Above all, we listen!

Just like our products, our partnerships are Carefully Crafted to benefit everyone.

Terumo Pharmaceutical Solutions

20180226.jpg

Accepting the award on behalf of Terumo, from left;

Hideo Arase, Director and Senior Executive Officer, Terumo Corporation, Managing Director, Terumo Asia Holdings. Ashit Sikka, Director, Terumo Pharmaceutical Solutions India.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.